Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + cyclophosphamide or docetaxel + cyclophosphamide-Duke University-breast cancer
- Development stage
- Unknown
- Lead developer
- Duke University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This entry refers to the neoadjuvant chemotherapy regimens doxorubicin plus cyclophosphamide (AC) and docetaxel plus cyclophosphamide (TC) as utilized in a Duke University-sponsored Phase II clinical trial. The study (NCT00821964) evaluated the use of genomic expression profiling to guide the selection between these two standard-of-care treatments for patients with HER2-negative early-stage breast cancer. Doxorubicin is an anthracycline that inhibits topoisomerase II and intercalates DNA; cyclophosphamide is an alkylating agent that induces DNA cross-linking; and docetaxel is a taxane that stabilizes microtubules. The trial aimed to determine if a genomic-guided approach could improve pathological complete response rates compared to random assignment.
- Other names
- AC regimenTC regimenAC or TCDoxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin + cyclophosphamide or docetaxel + cyclophosphamide-Duke University-breast cancer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + cyclophosphamide or docetaxel + cyclophosphamide-Duke University-breast cancer.